| Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: A population pharmacokinetic modelling and simulation study K Mehta, S Ravimohan, JG Pasipanodya, S Srivastava, C Modongo, ... Journal of Antimicrobial Chemotherapy 74 (10), 2994-3002, 2019 | 13 | 2019 |
| Predictions of bedaquiline and pretomanid target attainment in lung lesions of tuberculosis patients using translational minimal physiologically based pharmacokinetic modeling K Mehta, T Guo, PH Van Der Graaf, JGC van Hasselt Clinical Pharmacokinetics 62 (3), 519-532, 2023 | 12 | 2023 |
| Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches K Mehta, HP Spaink, THM Ottenhoff, PH van der Graaf, JGC van Hasselt Trends in Pharmacological Sciences 43 (4), 293-304, 2022 | 12 | 2022 |
| Predictions of bedaquiline central nervous system exposure in patients with tuberculosis meningitis using physiologically based pharmacokinetic modeling K Mehta, P Balazki, PH van der Graaf, T Guo, JGC van Hasselt Clinical Pharmacokinetics 63 (5), 657-668, 2024 | 3 | 2024 |
| Model‐based dose optimization framework for bedaquiline, pretomanid and linezolid for the treatment of drug‐resistant tuberculosis K Mehta, T Guo, PH Van der Graaf, JGC van Hasselt British Journal of Clinical Pharmacology 90 (2), 463-474, 2024 | 3 | 2024 |
| Pharmacogenetic variability and the probability of site of action target attainment during tuberculosis meningitis treatment: A physiologically based pharmacokinetic modeling … K Mehta, N Narayanan, SK Heysell, GP Bisson, S Subbian, N Kurepina, ... Tuberculosis 137, 102271, 2022 | 3 | 2022 |
| Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker‐driven precision dosing A Oni‐Orisan, N Srinivas, K Mehta, JL Das, TT Nguyen, GH Tison, ... Clinical and translational science 14 (3), 784-790, 2021 | 3 | 2021 |
| Quantitative systems pharmacology modeling framework of autophagy in tuberculosis: application to adjunctive metformin host-directed therapy K Mehta, T Guo, RS Wallis, PH van der Graaf, JGC van Hasselt Antimicrobial Agents and Chemotherapy 66 (8), e00366-22, 2022 | 2 | 2022 |
| Pharmacodynamic Exposure–Response Analysis of Fracture Count Data Following Treatment with Burosumab in Patients with XLH K Mehta, J Storopoli, N Ramwani, E Quattrocchi, J Gobburu, T Weber, ... The Journal of Clinical Pharmacology 65 (2), 253-260, 2025 | | 2025 |
| Model‐Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor‐Induced Osteomalacia MW Hruska, L Sid‐Otmane, NH Gosselin, E Quattrocchi, SK Lee, ... Clinical Pharmacology & Therapeutics 116 (6), 1606-1614, 2024 | | 2024 |
| Item Response Theory Quantifies the Relationship Between Improvements in Serum Phosphate and Patient‐Reported Outcomes in Adults With X‐Linked Hypophosphatemia K Mehta, NH Gosselin, K Insogna, O Barriere, E Quattrocchi, MW Hruska, ... Clinical Pharmacology & Therapeutics 116 (5), 1343-1351, 2024 | | 2024 |
| Model-Informed Drug Approach to Recommend Therapeutic Burosumab Dosing Regimens for Pediatric and Adult Patients with Tumor-Induced Osteomalacia M Hruska, L Sid-Otmane, N Gosselin, E Quattrocchi, SK Lee, MA Mascelli, ... | | 2024 |
| Quantitative Systems Pharmacology approaches for Development of Host-Directed Therapies against Mycobacterium tuberculosis infections K Mehta, H Spaink, T Ottenhoff, P van der Graaf, JGC van Hasselt ESS Open Archive eprints 212, 21226061, 2024 | | 2024 |
| an der, & Hasselt KM Mehta, T Guo, PH Graaf GC an, 519-532, 2023 | | 2023 |
| Rationale for the Clinical Use of Less Frequent Dosing of Mogamulizumab for T-Cell Lymphomas Using Population Pharmacokinetic and Exposure Response Analysis K Mehta, D Patel, R Vuppugalla, A Tudor, K Dwyer, M Hruska, ... Blood 138, 2475, 2021 | | 2021 |
| Population pharmacokinetic-pharmacodynamic analysis of KHK2455 in patients with locally advanced or metastatic solid tumors K Mehta, S Koshiba, M Hasegawa, T Tayama, D Marsteller, F Fox, Y Liu, ... Cancer Research 81 (13_Supplement), 1368-1368, 2021 | | 2021 |
| Leveraging innovative technology to generate drug response phenotypes for the A Oni-Orisan, N Srinivas, K Mehta Clinical and translational science, 14 (3), 2021 | | 2021 |
| Consider ASCPT in Your End-of-Year Giving D Wyatt, D Strauss, B Ray, K Mehta, T Vaidya, U Simonsson Clinical Pharmacology and Therapeutics 105 (1), 17-21, 2019 | | 2019 |
